SLN.L Regulatory News (SLN)

4 Oct 2006 11:56

SR Pharma plcHolding in CompanyLondon 4 October 2006 - SR Pharma plc (the Company) announces that it wasnotified today that following an increase in their holding of 1,171,100 SRPharma plc Ordinary Shares of 1p each, FMR Corp. and its direct and indirectsubsidiaries and Fidelity International Limited and its direct and indirectsubsidiaries, both being non-beneficial holders, held 6,929,796 SR Pharma plcOrdinary Shares, representing 7.45% of the issued share capital of the Company. - Ends - SR Pharma (www.srpharma.com)SR Pharma plc is a European biopharmaceutical company, listed on AIM. TheCompany has two operating subsidiaries Atugen AG (www.atugen.com) based inBerlin, Germany and Stanford Rook Ltd based in London, UK.Atugen is a leader in RNAi therapeutics. This Company has developed novel,chemically modified proprietary siRNA molecules ("AtuRNAi") and a proprietarydelivery system ("AtuPLEX") both of which have advantages over conventionalsiRNA molecules and their delivery systems. Currently Atugen and itscollaboration partners have lead molecules in pre-clinical development for avariety of therapeutic indications. Clinical development of AtuRNAi therapeuticmolecules for systemic applications in Atugen's oncology programs are targetedto start in 2007. Other AtuRNAi therapeutic programs of Atugen's collaboratorsare scheduled to commence in the second half of 2006.Stanford Rook Ltd is an immunotherapy based company which owns a proprietaryMycobacterium vaccae-based technology and related products, which have beenevaluated in clinical trials for the treatment of asthma, cancer andtuberculosis. In addition it has a number of other proprietaryimmunotherapeutic compounds and related intellectual property. Currently theCompany is in discussions with third parties regarding the co-development andout-licensing of M. vaccae and related products.Forward-Looking StatementsThis press release includes forward-looking statements that are subject torisks, uncertainties and other factors. These risks and uncertainties couldcause actual results to differ materially from those referred to in theforward-looking statements. All forward-looking statements are based oninformation currently available to SR Pharma and SR Pharma assumes noobligation to update any such forward-looking statements.Enquiries:For further information, please contact the following:SR Pharma plc Atugen AG +44(0)20 7307 1620 +49(0)30 9489 2800 Iain Ross, Chairman Thomas Christĩly, Chief Executive Officer Melvyn Davies, Finance Director Dr. Klaus Giese, Chief Scientific Officer mail@srpharma.com Northbank Communications +44(0)20 7886 8150 Sue Charles Justine Lamond srpharma@northbankcommunications.com ENDSR PHARMA PLC